Abstract
In recent years, we have witnessed a revolution in the treatment of coronary artery disease. The development and improvement of drug eluting stents (DES) have lowered the incidence of restenosis to one-digit figures. In the search for a superior efficacy, animal models have played a key role. The classical swine model of coronary stenting remains the preferred model to measure restenosis, although the rabbit iliac artery stenting has become an accepted alternative. After widespread clinical use of DES, an unforeseen complication arose: late stent thrombosis. In a back-to-bench step, some data from animal models helped to explain the phenomenon. A delayed and incomplete vascular healing was detected. Toxic and hypersensitivity reactions to polymers and/or drugs seem to be the underlying causes. So, translational research focused on the safety aspect of these devices: development of better drug carriers as absorbable polymers or fully bioresorbable scaffolds, selection of different drugs and assessment of the re-endothelialization process. We review and evaluate the efficacy and safety of coronary stents in different animal models. Further improvements in this field such as, the selection of better animal models (e.g. hyperlipidemic, diabetic, atherosclerotic) that closely mimic the clinical setting and longer follow-up periods to detect late complications are also discussed.
Keywords: Animal model, drug eluting stent, endothelium, inflammation, percutaneous coronary intervention, safety, stent thrombosis vascular healing
Current Vascular Pharmacology
Title:Preclinical Evaluation of Coronary Stents: Focus on Safety Issues
Volume: 11 Issue: 1
Author(s): Armando Perez de Prado, Claudia Perez-Martinez, Carlos Cuellas, Jose M. Gonzalo-Orden, Alejandro Diego, Marta Regueiro, Beatriz Martinez-Fernandez, Jose R. Altonaga, J. Francisco G. Marin and Felipe Fernandez-Vazquez
Affiliation:
Keywords: Animal model, drug eluting stent, endothelium, inflammation, percutaneous coronary intervention, safety, stent thrombosis vascular healing
Abstract: In recent years, we have witnessed a revolution in the treatment of coronary artery disease. The development and improvement of drug eluting stents (DES) have lowered the incidence of restenosis to one-digit figures. In the search for a superior efficacy, animal models have played a key role. The classical swine model of coronary stenting remains the preferred model to measure restenosis, although the rabbit iliac artery stenting has become an accepted alternative. After widespread clinical use of DES, an unforeseen complication arose: late stent thrombosis. In a back-to-bench step, some data from animal models helped to explain the phenomenon. A delayed and incomplete vascular healing was detected. Toxic and hypersensitivity reactions to polymers and/or drugs seem to be the underlying causes. So, translational research focused on the safety aspect of these devices: development of better drug carriers as absorbable polymers or fully bioresorbable scaffolds, selection of different drugs and assessment of the re-endothelialization process. We review and evaluate the efficacy and safety of coronary stents in different animal models. Further improvements in this field such as, the selection of better animal models (e.g. hyperlipidemic, diabetic, atherosclerotic) that closely mimic the clinical setting and longer follow-up periods to detect late complications are also discussed.
Export Options
About this article
Cite this article as:
Perez de Prado Armando, Perez-Martinez Claudia, Cuellas Carlos, M. Gonzalo-Orden Jose, Diego Alejandro, Regueiro Marta, Martinez-Fernandez Beatriz, R. Altonaga Jose, Francisco G. Marin J. and Fernandez-Vazquez Felipe, Preclinical Evaluation of Coronary Stents: Focus on Safety Issues, Current Vascular Pharmacology 2013; 11 (1) . https://dx.doi.org/10.2174/1570161111309010074
DOI https://dx.doi.org/10.2174/1570161111309010074 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Downstream Processing for Production of Value Added Products from Coconut
Current Biochemical Engineering (Discontinued) Chlorophytum borivilianum: A White Gold for Biopharmaceuticals and Neutraceuticals
Current Pharmaceutical Biotechnology Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery
Current Diabetes Reviews Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Circulating and Vascular Bioactive Factors During Hypertension in Pregnancy
Current Bioactive Compounds New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Intestinal Targeting of Drugs: Rational Design Approaches and Challenges
Current Topics in Medicinal Chemistry Swimming Impacts on Pancreatic Inflammatory Cytokines, miR-146a and NF-кB Expression Levels in Type-2 Diabetic Rats
Current Diabetes Reviews Allele Frequencies of Two Main Metformin Transporter Genes: SLC22A1 rs628031 A>G and SLC47A1 rs2289669 G>A among the Javanese Population in Indonesia
Current Pharmacogenomics and Personalized Medicine The Pharmacology of Diabetic Complications
Current Medicinal Chemistry A Patient with COVID-19 Disease in a Referral Hospital in Iran: A Typical Case
Infectious Disorders - Drug Targets PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Current Pharmaceutical Design The Impact of In Vitro Fertilization on the Health of the Mother and the Offspring
Current Women`s Health Reviews Heightened Attention for Wnt Signaling in Diabetes Mellitus
Current Neurovascular Research Modulation of the Lipid Profile, Hepatic and Renal Antioxidant Activities, and Markers of Hepatic and Renal Dysfunctions in Alloxan-Induced Diabetic Rats by Virgin Coconut Oil
Endocrine, Metabolic & Immune Disorders - Drug Targets Coronary Artery Bypass Graft in HIV-Infected Patients: A Multicenter Case Control Study
Current HIV Research CSII as an Alternative Therapeutic Strategy for Managing Type 2 Diabetes: Adding the Indian Experience to a Global Perspective
Current Diabetes Reviews In Silico Bioactivity Prediction of Methoxime-3,4-dephostatin Derivatives on Human PTP1B: Search for Novel Antidiabetic Leads
Letters in Drug Design & Discovery Medical Management and Risk Reduction of the Cardiovascular Effects of Underwater Diving
Current Vascular Pharmacology Oxidative Stress in the Pathogenesis/Treatment of Atherosclerosis
Current Nutrition & Food Science